Distribución mundial de la producción de vacunas

Known Vaccine Manufacturing Capacity – J&J

CURRENT AS OF JANUARY 28, 2021 NON-EXHAUSTIVE EXAMPLES FOR ILLUSTRATION PURPOSES ONLY

Annualised Capacity by YE 2021

Partner	Location	Capacity	New or existing
	2	Many thousands of doses	repurposed
	Acom, India		Refit/ repurposed
	Baltimore, MD, USA		New plant
Aspen (Pharma- care)	Elizabeth, South Africa	300M	Refit/ repurposed
River	Grand Rapids, MI, USA	Not	Existing
Catalent	Bloomington, IN, USA; Anagni, Italy		Existing



Known Vaccine Manufacturing Capacity – BioNTech/Pfizer


CURRENT AS OF JANUARY 28, 2021

NON-EXHAUSTIVE

EXAMPLES FOR ILLUSTRATION PURPOSES ONLY

			ed Capacity	by YE 202	1
□ DS: Drug substance ○ DP: Drug product △ FF: Fill-and-finish	Annual Capacity ¹ 2B CMO Strategic partner (e.g. PharmaCo)	Partner	Location	Capacity	New or existing
LI DO, Drug substance O DP, Drug product Z PP, Pil-and-fillian	• Gino • Strategic partiel (a.g. Pharmaco)	Pfizer	Saint Louis, MO, USA;	1.3B	Refit/ repurposed
	· /		Andover, MA, USA;		
			Kalamazoo, MI, USA;		
Rentschler, Milford, Massachusetts	Sanofi Germany		Puurs, Belgium;		
Pfizer Andreas	Pfizer	BioNTech	Marburg, Germany	750m	New purchase
Pfizer Andover, Kalamazoo, Massachusetts Michigan	Beigium BioNTech	Sanofi	Frankfurt, Germany	125m	Refit/ repurposed
Saint Louis, Missouri	Germany Siegfried,	Rentschler	Laupheim, Germany;	Not disclosed	Refit/ repurposed
	Dermapharm,		Milford, MA, USA		
	Germany	Siegfried	Hameln, Germany	Not disclosed	Refit/ repurposed
		Derma- pharm	Brehna, Germany	Not disclosed	Refit/ repurposed
		Polymun	Not disclosed	Not disclosed	Refit/ repurposed

Known Vaccine Manufacturing Capacity – Moderna




Known Vaccine Manufacturing Capacity – Novavax

NON-EXHAUSTIVE

EXAMPLES FOR ILLUSTRATION PURPOSES ONLY

Annualised Capacity by YE 2021

Partner	Location	Capacity	New or existing
Takeda	Japan	250M	Refit/ repurposed
Serum Institute of India	Pune, India	18	Refit/ repurposed
FUJIFILM	Morrisville, NC, USA; Texas, USA; UK	US: 100M UK: 180M	Existing
SK Bioscience	Andong L- house, South Korea		N/A
Biofabri	Spain	Not disclosed	N/A
PolyPeptide Group	US; Sweden	Not disclosed	N/A
AGC Biologics		Not disclosed	N/A
Endo Inter- national		Not disclosed	N/A



Known Vaccine Manufacturing Capacity – AstraZeneca²

	Annual Capacity ⁴ 3.2B
DS: Drug substance O DP: Drug product 🛆 FF: Fill-and-finish	CMO Strategic partner (e.g. PharmaCo)
Albany Molecular Research, New Mexico New Mexico Albany Molecular Research, Catalent New Mexico Albany Molecular Research, Catalent Marviand Symbolsis BioSolutions Marviand Molecular Symbolsis BioSolutions Marviand Molecular BioSolutions Marviand Molecular BioSolutions Marviand Molecular BioSolutions Marviand Molecular BioSolutions Marviand Molecular Marviand Molecular BioSolutions Marviand Molecular BioSolutions Marviand Molecular	Wockhardt UK Novasep Belgium Hais, Netherlands Catalent, Italy SK Bioscience China Serum Institute, India

Annualised Capacity by YE 2021

Partner	Location	Capacity	New or existing
Scotland Symbiosis	Stirling, Scotland	Not disclosed	N/A.
Serum institute	India	18	RefitRepurpose
BioKangtai	China.	200M	NJA.
Siam Bioscience	Thailand	Notdisclosed	NA.
R-Pharm	Moscow, Russia	Not disclosed	N/A
Flocruz	Bradi	480M	N/A
CSL	Australia	30M	Existing
mAbrience	Argentina; Nexico	200M	NA.
Emergent BioSolutions	Baltimore, MD, USA	Hundreds of millions of dos es	New
Cobra	Newcastle, UK	1210	N/A
Haltx	Netherlands	Not disclosed	N/A
Oxford Biomedica	Oxbow, UK	Not disclosed	Existing
Catalent	Harmans, MD, USA; Anagni, Italy	Not disclosed	Existing
Novasep	Seneffe, Belgium	Not disclosed	Existing
SK Blosdence	Andong, China	Not disclosed	N/A
Albany Nolecular Research	Albuquerque, NM, USA	Millions of dos es	NJA.
Woekhardt	North Wales, UK	100M	NJA.

1 For COVID-19 vaccine production; no other mRNA vaccines are currently commercially available...

2. Reported agreements with 20 contract manufacturing organisations in July 30, 200 H1 earnings call